Cara Therapeutics (NASDAQ: CARA) reported Q3 EPS of ($0.19), $0.08 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.77 million.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.